Premium
Phosphate Binders in Chronic Kidney Disease and End‐Stage Renal Disease: A Patient‐Centered Approach
Author(s) -
Novak James E.,
Szczech Lynda A.
Publication year - 2009
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/j.1525-139x.2008.00514.x
Subject(s) - medicine , sevelamer , kidney disease , intensive care medicine , disease , phosphate , phosphate binder , clinical trial , hyperphosphatemia , biochemistry , chemistry
Disorders of calcium and phosphorus metabolism are associated with significant morbidity and mortality in patients with advanced chronic kidney disease. These patients typically require oral phosphate binders to maintain phosphorus homeostasis, but the choice of which among several agents to use has been actively investigated and debated. Recent debate has been polarized between those who favor calcium‐based binders for their proven efficacy and relatively low cost and those who favor sevelamer for its putative beneficial effects on inflammatory biomarkers and vascular calcification. This review summarizes the current state of the art of prescribing phosphate binders, ranging from large‐scale clinical trials to focused mechanistic studies, and proposes that the available evidence does not conclusively prove the relative superiority of any one binder.